Journal of Neurodegenerative Diseases / 2013 / Article / Tab 1

Clinical Study

The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease

Table 1

Demographic and clinical features of 128 patients with Alzheimer's disease with/or without diabetes mellitus (T2-DM).

AD with T2-DM
(group A)
= 61
AD without T2-DM
(group B)
= 65

Age; years, M (SD)72 (6.8)74.2 (5.7).32
Sex (M/F)22/3929/36.05
MMSE score; M (SD)20.7 (4.4)21.8 (4.9).32
MADRS score15.816.3.42
Smokers; , %12; 2018; 28.09
Educational level; years, M (SD)10.6 (4.5)11.7 (5.4).21
Disease duration; years, M (SD):
 (a) Alzheimer disease 5.3 (2.1)4.9 (2.8).12
 (b) Diabetes Mellitus 7.8 (3.7)////
Anti-Alzheimer drugs: n; %
 (a) Donezepil 21; 3419; 29.23
 (b) Rivastigmine28; 4626; 40.18
 (c) Galantamine3; 43; 4.6.24
 (d) Memantine4; 63; 4.6.43
Antipsychotic use: n; %
 (a) Total 2127.09
 (b) Atypical antipsychotic10; 1615; 23.06
 (c) Typical antipsychotic11; 1211; 18.12
Concomitant diseases
 (a) Total pathologies5630.001
 (b) Past2513.03
 (c) Current3117.02
Current Pathologies
 (a) Hypertension2010.02
 (b) Hypercholesterolemia117.08
Regresses pathologies
 (a) Ischemic heart disease139.05
 (b) Others pathologies124.02

MMSE: Mini-Mental State Examination; MADRS: Montgomery Asberg Depression Rating Scale. Values are expressed as mean (SD) unless otherwise indicated. P value of 0.05 was considered statistically significant.